ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2049

Descriptive Analysis of a Cohort of Neurosarcoidosis Mimics

Shivani Rangaswamy1, Andrea Lopez1, Megumi Sugita1, Ethan Eyman1, Elijah Lackey1 and Jeffrey Shen2, 1Duke University Hospital, Durham, 2Division of Rheumatology and Immunology, Duke University Department of Medicine, Durham, NC

Meeting: ACR Convergence 2025

Keywords: Neuroimaging, neurology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2015–2051) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Sarcoidosis is a granulomatous multi-system disease with nervous system involvement in 5-20% of patients. Diagnosis of neurosarcoidosis is challenging due to its broad spectrum of phenotypic and radiographic manifestations. This study leverages a North American registry of patients misdiagnosed as neurosarcoidosis and provides a descriptive analysis of diagnostic tools used to evaluate patients for neurosarcoidosis.

Methods: Two hundred and forty-four patients with a diagnosis code of neurosarcoidosis were identified between 2010 and 2020 at a tertiary care academic institution. Chart review by a neurologist and rheumatologist identified 26 patients who were misdiagnosed as neurosarcoidosis and later found to have an alternative diagnosis. Twenty-three of these charts were reviewed to identify demographic data, relevant laboratory studies, neuroimaging, and pathology. Neuroimaging of a subgroup of 6 neurosarcoidosis mimics and 6 neurosarcoidosis controls were reviewed by 5 neuroimmunology specialists in a blinded survey to obtain additional data regarding radiographic diagnostic certainty of neurosarcoidosis and its mimics.

Results: Over half (52%) of the cohort was diagnosed with another primary CNS process, most commonly multiple sclerosis. Other common mimics included lymphoma (9%), infection (13%), primary ophthalmic conditions (17%), and rheumatoid arthritis (9%). Angiotensin converting enzyme (ACE) was elevated at least once in 40% of the patients. Cerebrospinal fluid (CSF) analysis showed an elevated white blood cell count and protein in approximately 1/3 of the cohort and low glucose in only 1 patient with rheumatoid arthritis. Of the 17 patients who had a biopsy of some tissue for their neurosarcoidosis workup, 12 had granulomas on pathology. Only 1 of 7 patients with a brain biopsy had granulomas on pathology. The majority of patients had MRIs of the brain and/or spine and the most common radiographic patterns were pachymeningeal and parenchymal enhancement.In a radiographic review survey of 6 neurosarcoidosis mimics and 6 neurosarcoidosis controls, 4 out of 6 mimics and 5 out of 6 controls were correctly identified based on group consensus. The idiopathic hypertrophic pachymeningitis (IHP) case and rheumatoid arthritis case were incorrectly diagnosed as neurosarcoidosis based on group consensus. One neurosarcoidosis control was felt to be most likely IgG4-related disease (IgG4-RD) by 2 reviewers and neurosarcoidosis by 2 reviewers. Pre-existing knowledge of a pulmonary sarcoidosis diagnosis appeared to influence diagnostic certainty of neurosarcoidosis.

Conclusion: Common mimics of neurosarcoidosis include infection, lymphoma, rheumatoid arthritis, another CNS process, and primary ophthalmic processes. Laboratory and CSF studies may not be sensitive for neurosarcoidosis. MRI review by a neurosarcoidosis specialist can help differentiate neurosarcoidosis from mimics with radiographic differences, such as infection or multiple sclerosis, and spare the patient a biopsy. Biopsy may be needed to distinguish neurosarcoidosis from diseases that are radiographically similar, such as IHP or IgG4-RD. Limitations include small sample size and limited follow-up.

Supporting image 1Serum and CSF Studies

Supporting image 2Pathology and Neuroimaging

Supporting image 3Neuroimaging Survey Results


Disclosures: S. Rangaswamy: None; A. Lopez: None; M. Sugita: None; E. Eyman: None; E. Lackey: Amgen, 1, TG Therapeutics, 1; J. Shen: None.

To cite this abstract in AMA style:

Rangaswamy S, Lopez A, Sugita M, Eyman E, Lackey E, Shen J. Descriptive Analysis of a Cohort of Neurosarcoidosis Mimics [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/descriptive-analysis-of-a-cohort-of-neurosarcoidosis-mimics/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/descriptive-analysis-of-a-cohort-of-neurosarcoidosis-mimics/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology